Identification of therapeutically relevant tumour-associated alterations of the RA signalling pathway in glioblastoma

Patricia Flynn

Patricia Flynn was awarded with a Musgrave PhD Scholarship in partnership with Breakthrough Cancer Research. Patricia worked in Dr. Andre Toulouse’s lab at University College Cork on glioblastoma.

Glioblastomas are aggressive primary brain tumours with limited treatment options and a poor survival rate. Natural and synthetic vitamin A derivatives called retinoids have been shown to reduce the growth of tumours in various cancer types. This effect is mediated by a group of proteins called the retinoic acid receptors that control molecular pathways that lead to the promotion or suppression of cell growth in target tissues. The final effect of this is determined by which retinoic acid receptors are present in the cells.

We propose to investigate which of these receptors are expressed in glioblastomas and associate their expression with the tumour properties. Once receptors that are preferentially associated with slow tumour growth are identified, we will study the effects of these proteins on tumour characteristics in a cell model of glioblastoma.

Our aim is to identify proteins that reduce the growth of glioblastoma cells and attempt modulate their activity using specific retinoids. In this way retinoid therapy might become a novel therapeutic option to offer to carefully selected patients.

 

RESEARCH FINDINGS

Conference Presentations

Cancer Research UK Brain Tumour Conference 2024, London, UK. Title: “Retinoid specificity in mediating growth suppression in glioblastoma stem cells”.

 

Awards

University College Cork – winner of Public Engagement Award 2024

Back

Start year
2021
End year
2024
Principal Investigators
Dr. Andre Toulouse and Dr. Colette Hand
Researcher
Patricia Flynn
Institution
University College Cork
Grant Funding
Musgrave PhD Scholarship in partnership with Breakthrough Cancer Research
Linked Breakthrough Research Priorities
research-priorities-icon1

Increase research investment into poor prognosis cancers and currently incurable cancers prioritising lung, oesophageal, ovarian, pancreatic, brain, liver and stomach cancers.

research-priorities-icon4

Fund research which aims to improve the effectiveness or specificity of current cancer therapies including investing in biomarkers discovery, nutrition and therapeutic delivery.